Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Prelude Therapeutics (PRLD) Other Gross PP&E Adjustments (2023 - 2026)

Prelude Therapeutics' Other Gross PP&E Adjustments history spans 4 years, with the latest figure at -$26.8 million for Q1 2026.

  • On a quarterly basis, Other Gross PP&E Adjustments rose 5.43% to -$26.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$26.8 million, a 5.43% increase, with the full-year FY2025 number at -$36.1 million, down 12.72% from a year prior.
  • Other Gross PP&E Adjustments hit -$26.8 million in Q1 2026 for Prelude Therapeutics, up from -$36.1 million in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for PRLD hit a ceiling of -$26.8 million in Q1 2026 and a floor of -$36.1 million in Q4 2025.
  • Historically, Other Gross PP&E Adjustments has averaged -$30.0 million across 4 years, with a median of -$29.4 million in 2024.
  • The widest YoY moves for Other Gross PP&E Adjustments: up 5.95% in 2025, down 12.72% in 2025.
  • Tracing PRLD's Other Gross PP&E Adjustments over 4 years: stood at -$32.5 million in 2023, then increased by 1.61% to -$32.0 million in 2024, then fell by 12.72% to -$36.1 million in 2025, then grew by 25.73% to -$26.8 million in 2026.
  • Business Quant data shows Other Gross PP&E Adjustments for PRLD at -$26.8 million in Q1 2026, -$36.1 million in Q4 2025, and -$27.5 million in Q3 2025.